Tricagrelor; New landmark in the evolution of Antiplatelet Therapy

By: Dr. Smitha Hegadi, Medical Analyst, Aissel Solutions

The understanding of platelet biology has yielded several targets which gave new dimensions to management of coronary syndromes. Over the years this understanding resulted in the metamorphosis of treatment of acute coronary syndromes with aspirin and Clopidogrel. But the limitations of this new therapy kept the research live and today we have Tricagrelor, new landmark in the evolution of antiplatelet therapy. Tricagrelor has qualities like faster onset of action, resistant to drug interactions which make it beneficial over the existing standard therapy.

Tissue Engineered Vascular Grafts: New therapy for Coronary Revascularization

By: Smita Kadam, Data Analyst, Aissel Solutions
 

Despite over 50 years of research in the field of Synthetic Materials, native Vein and Artery segments are most commonly used for Revascularization procedures in Cardiac Surgery. Unfortunately suitable Veins or Arteries are not always available for peripheral or Coronary Revascularization, on the other hand artificial grafts do not grow with the body and frequent replacement is must. More over artificial grafts are susceptible to infection, poor durability and calcification when being attacked by the immune system. But the development of functional Tissue Engineered Vascular Grafts (TEVG) using tissue engineering techniques and engineering principles has the potential of tremendously effecting Coronary and Peripheral Artery Bypass Surgeries.